Clemson University
Bifunctional Fusion Protein PDL1sFv/MICAe for Cancer Immunothearpy
Abstract
dc:description.abstractCancer immunotherapy has highlighted the importance of immune checkpoint blockade and innate immune cell engagement in battling tumor-mediated immune suppression in the past few decades. However, with cancer development, advanced tumors are often found to develop resistance towards single-target immunotherapy due to the complexity of the immunosuppressive mechanisms within the tumor microenvironment (TME). To address this, we developed a novel bifunctional fusion protein, PDL1sFv/MICAe, which combines the tumor-targeting capability of an anti-PDL1 single-chain variable fragment (sFv) with the NK cells immunostimulatory properties of the MICA extracellular domain. In vitro functional assays revealed that PDL1sFv/MICAe significantly enhanced cytotoxicity towards natural killer (NK) cells against PD-L1 positive cancer cells despite minimal changes in IFN-γ or granzyme B secretion, suggesting that the PDL1sFv/MICAe promotes NK cell activation via non-canonical mechanisms. Similarly, cytotoxic T cells, which often exhibit suppressed function in PDL1–rich environments, showed rescued cytotoxicity upon treatment, independent of IL-10 regulation. Post-treatment transcriptomic analysis of NK cells revealed significant upregulation of genes involved in signal transmission pathways rather than genes classically linked to cell-mediated killing or stress responses. These findings suggest a possible alteration in NK cell signaling dynamics in the observed functional enhancement in cytotoxicity. Although no synergistic effect was observed in co-culture assays involving NK cells and cytotoxic T cells, the fusion protein effectively activated each cell type independently towards PDL1-positive cancer cells. These results highlight the therapeutic potential of PDL1sFv/MICAe as a dual-function protein capable of reactivating suppressed immune responses of T cells while inducing NK cell cytotoxicity within the TME. By engaging both adaptive and innate immunity, PDL1sFv/MICAe represents a promising strategy for improving immunotherapy outcomes in solid tumors resistant to conventional treatments.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy (PhD)
- Level thesis:degree_level
- Dissertation
- Discipline thesis:degree_discipline
- Biological Sciences
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Li, Junyi
- Contributors dc:contributor
-
- Yanzhang Wei
- Lesly A. Temesvari
- Charles D. Rice
- Zhicheng Dou
Subjects
dc:subject × 9Identifiers
dc:identifier.*- Repository record dc:identifier
- https://open.clemson.edu/all_dissertations/3988